仁和福百泰品牌怎么样 申请店铺

我要投票 仁和福百泰在医疗保健行业中的票数:355 更新时间:2025-08-15
仁和福百泰是哪个国家的品牌?「仁和福百泰」是 洛阳伊贝生物科技有限公司 旗下著名品牌。该品牌发源于河南/洛阳/老城区,由创始人朱晓娜在2018期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力仁和福百泰品牌出海!将品牌入驻外推网,定制仁和福百泰品牌推广信息,可以显著提高仁和福百泰产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

仁和福百泰怎么样

仁和药业,深交所上市公司(000650),公司一直致力于传统与高科技医药产品研发与推广,通过满足广大消费者健康需要而实现自身价值,是国家创新型试点企业。旗下拥有1家上市公司,3家医药科研机构,15家药品、保健品生产企业,先后研制、开发了1000多个医药、保健产品。自创建以来,仁和集团在销售收入、贡献税收等主要经济指标方面,实现了连续6年翻番增长,10年增长70倍的优异成绩。

仁和福百泰——系仁和旗下的核心新零售品牌产品,由主板上市公司中国仁和制药集团荣誉出品。仁和福百泰品牌专注与筋骨养护,源于百年秘制古方,久经传承,拥有着 全国先进的生产技术和GMP权威检测认证,集传统文化与现代工艺结合,专注为颈椎、肩周、腰椎、筋骨酸痛人群提供健康又安全的筋骨养护产品,促使产品向品质化、绿色化、品牌化、生态化方向跨越发展。

洛阳伊贝生物科技有限公司位于“九朝古都”洛阳,公司一直专注于大健康行业,是一家立足于微商新零售+健康养生行业技术研发,以分销、定制分销、品牌孵化等多种模式进行线上线下融合拓展。公司始终坚持以品牌、技术为基础创造更佳的产品和服务,用全新的经济模式,正式启幕。

公司现有一流的产品研发团队,市场调研团队、国内顶尖营销策划团队,线上线下引流的专业团队,依托仁和药业的市场知名度、可信度,产品过硬的品质和效果,2019,仁和福百泰开辟膏贴行业新蓝海!

未来,我们将携手共进,超越梦想,继续为消费者提供健康、有品质的生活,共创互联网大健康时代!

Renhe Pharmaceutical Co., Ltd., a listed company of Shenzhen Stock Exchange (000650), has been committed to the research and development and promotion of traditional and high-tech pharmaceutical products, realizing its own value by meeting the health needs of consumers. It is a national innovative pilot enterprise. It has 1 listed company, 3 pharmaceutical research institutions, 15 pharmaceutical and health product manufacturers, and has developed more than 1000 pharmaceutical and health products. Since its establishment, Renhe group has achieved six consecutive years of double growth in terms of sales revenue, contribution tax and other major economic indicators, and 70 times growth in 10 years. Renhe fubaitai, the core new retail brand product of Renhe, is produced by the main board listed company Renhe pharmaceutical group of China. The brand of Renhe fubaitai focuses on the maintenance of muscles and bones, which is originated from a century old secret formula and has been passed down for a long time. It has the national advanced production technology and GMP authoritative testing certification. It integrates traditional culture with modern technology, and focuses on providing healthy and safe muscles and bones maintenance products for the people with cervical, shoulder, lumbar, and muscles and bones pain, so as to promote the quality, green, brand and ecology of the products The direction spans development. Luoyang ibei Biotechnology Co., Ltd. is located in Luoyang, the ancient capital of the nine dynasties. The company has been focusing on the big health industry. It is based on the new retail of wechat business + technology research and development of health care industry, and integrates online and offline development with distribution, customized distribution, brand incubation and other modes. The company always insists on creating better products and services based on brand and technology, and officially opens with a new economic model. The company has a first-class product R & D team, a market research team, a top domestic marketing planning team, an online and offline professional team, relying on Renhe pharmaceutical's market awareness, credibility, and excellent product quality and effect, in 2019, Renhe fubaitai will open up a new blue ocean of paste industry! In the future, we will work together to surpass our dreams and continue to provide consumers with health Quality of life, create a great Internet health era!

本文链接: https://brand.waitui.com/cd45fdcad.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

南向资金净买额达300亿港元

36氪获悉,南向资金净买额达300亿港元,为今年4月9日以来首次

2小时前

礼来投资AI制药公司Superluminal

当地时间8月14日,礼来宣布与美国AI制药公司Superluminal签署价值13亿美元的交易,以加速AI药物研发,尤其是开发针对肥胖症及其他心脏代谢性疾病治疗的小分子药物。Superluminal是一家总部位于美国波士顿的AI制药初创型企业,该公司获得了包括英伟达在内的资本投资。(第一财经)

2小时前

菲律宾政府为三星10亿美元项目提供激励措施

菲律宾商务通消息,据《菲星报》8月14日报道,菲经济特区管理署(PEZA)称,计划在本季度内敲定激励方案,其中包括为三星电机菲律宾公司(SEMPHIL)计划投资的10亿美元项目提供的电力补贴,各方已就电价达成一致,将于本周将方案提交财政激励审查委员会(FIRB)审批,FIRB批准后,将提交总统办公室(OP),OP批准后,将流转至PEZA,预计三季度完成审批程序。(界面)

2小时前

工银资本等在四川成立兴眉工融基金

36氪获悉,爱企查App显示,近日,四川兴眉工融股权投资基金合伙企业(有限合伙)成立,执行事务合伙人为工银资本管理有限公司、四川兴川重点项目股权投资基金管理有限公司,出资额10亿元人民币,经营范围包括以私募基金从事股权投资、投资管理、资产管理等活动等。合伙人信息显示,该基金由眉山东坡国有资本投资运营集团有限公司、工银金融资产投资有限公司、四川兴川重点项目股权投资基金管理有限公司等共同出资。

2小时前

中国核建:截至2025年7月累计新签合同904.8亿元

36氪获悉,中国核建公告,截至2025年7月,公司累计新签合同904.80亿元,累计实现营业收入582.29亿元。

2小时前

本页详细列出关于仁和福百泰的品牌信息,含品牌所属公司介绍,仁和福百泰所处行业的品牌地位及优势。
咨询